Abstract
Treatment of severe juvenile idiopathic arthritis (JIA) represents a serious challenge. This study investigates the efficacy and safety of repeat courses of rituximab in patients with different forms of JIA refractory to infliximab and standard immunosuppressive therapy. Patients (n = 55; age 2.3–17.0 years) with severe polyarticular and systemic JIA (International League of Association for Rheumatology diagnostic criteria) received rituximab (one intravenous infusion/week for 4 weeks, 375 mg/m2 per dose). Efficacy was assessed using the American College of Rheumatology Pediatric (ACR Pedi) criteria. The primary endpoint was an ACR Pedi 30 response at week 24. At week 24, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 50%, and 40% of patients, respectively. By week 96, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 93%, and 93% of 25 patients, respectively. Remission was recorded in 25%, 52%, 75%, and 98% of patients following the first (24 weeks), second (48 weeks), third (72 weeks), and fourth (96 weeks) courses of rituximab, respectively. Rituximab treatment significantly reduced the number of systemic manifestations at week 12 and also enabled 52% of patients to achieve remission of arthritis by week 48. This study supports the efficacy of rituximab in patients with severe forms of JIA, refractory to several prior agents.
Similar content being viewed by others
References
Gabriel SE (2001) The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27:269–281
El Gabalawy HD, Lipsky PE (2002) Why do we not have a cure for rheumatoid arthritis? Arthritis Res 4(Suppl 3):S297–S301
Nasonov EL (2005) Pharmacotherapy of rheumatoid arthritis: the 21st century. Klin Med Mosk 83:8–12
Nasonov EL (2006) Treatment of rheumatoid arthritis: current problem state. Russ Med J 14:573–577
Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43:1849–1857
Cassidy JT (2005) Textbook of paediatric rheumatology, 5th edn. Elsevier, Philadelphia
Alexeeva EI, Litvitsky PF (2007) Juvenile rheumatoid arthritis. Etiology. Pathogenesis. Clinics. Diagnostic and treatment algorithms. Guidelines for physicians, academicians, researchers. In: Baranov AA (ed) Academician of the Russian Academy of Medical Sciences, Moscow, pp 325–339
Nasonov EL (2008) Rituximab in the treatment of rheumatic diseases. Nauchno-prakticheskaya revmatologia 1:3–10
Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564–576
Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744
Edwards JC, Cambridge G, Leandro MJ (2006) B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20:915–928
Nasonov EL (2006) New trends in the treatment of rheumatoid arthritis: perspectives of use of monoclonal anti-B-lymphocyte antibodies (rituximab). Russ Med J 25:1778–1782
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445
Edwards JC, Szczepañski L, Szechiñski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepañski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68:216–221
Foeldvari I, Bica B, Dedeoglu F (2009) Efficacy of rituximab in RF factor negative juvenile idiopathic arthritis. Ann Rheum Dis 68(Suppl 3):502, abstract FRI0450
El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP (2007) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150:376–382
Feito JG, Pereda CA (2009) Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 15:363–365
Kasher-Meron M, Uziel Y, Amital H (2009) Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatol Oxf 48:445–466
Kuek A, Hazleman BL, Gaston JH, Ostör AJ (2006) Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatol (Oxf) 45:1448–1449
Narváez J, Díaz-Torné C, Juanola X, Geli C, Llobet JM, Nolla JM, Díaz-López C (2009) Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 68:607–608
Alexeeva EI, Bzarova EL, Semikina ASS (2006) Experience of the use of rituximab in a female patient with systemic juvenile rheumatoid arthritis. Curr Ped (Russian) 5:96–100
Alexeeva EI, Bzarova EL, Valieva CI, Semikina EL, Akulova SS (2008) Rituximab: new opportunities in the treatment of severe refractory juvenile arthritis. Curr Ped (Russian) 7:22–30
Denisova RV, Alexeeva EI, Albitskiy V, Yu et al (2009) Reliability, validity, and responsiveness of the Russian versions of the Pediatric Quality of Life Inventory™ Generic Core Scales and Rheumatology Module. Curr Ped (Russian) 8(1):30–41
Denisova RV, Alexeeva EI, Albitskiy V Yu et al (2008) Psychometric evaluation of Russian versions of the Pediatric Quality of Life Inventory™ Generic Core Scales and Rheumatology Module for children aged from 2 to 4 years old. Curr Ped (Russian) 7(5):39–45
Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31:2290–2294
van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558–567
Dass S, Vital EM, Emery P (2007) Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 56:2715–2718
Acknowledgments
Support for third-party writing assistance for this manuscript was provided by F. Hoffmann-La Roche.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexeeva, E.I., Valieva, S.I., Bzarova, T.M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 30, 1163–1172 (2011). https://doi.org/10.1007/s10067-011-1720-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1720-7